OrbusNeich的Genous支架有望获得创新奖

一种新型支架叫做Genous生物工程R支架，是以天然愈合途径为基础，对抗血栓形成并将血管狭窄降低至最小。该支架已经获得了CE标志。

这种Genous支架的开发商是香港的OrbusNeich公司，该公司已经被挑选为Frost & Sullivan (Palo Alto, CA, USA)2005年技术创新奖的获得者。每年，这项大奖授予那些开展新研究并导致创新的公司，这些研究已经或者即将对产业带来显著的贡献。

Genous支架能够以快速和可控制的方式促进组织愈合，而不是抑制愈合，包括内皮细胞覆盖，强大的抗增殖药物释放支架。一项正在进行的临床研究叫做HEALING II(健康内皮细胞加速排列抑制新血管内皮生长)，其初步研究结果的分析显示，接受该支架的患者疾病的临床转归较好。一项HEALING III多因素临床研究不久即将开始，评估Genous的Statin治疗与无覆盖金属支架的疗效。

“Genous不是一种药物释放支架，没有聚合体或者药物。 ” 销售与市场部副总裁David Camp指出。“这种支架使用抗体进行覆盖，能够捕获患者自身循环中内皮细胞的祖细胞。这样不仅能够将再狭窄的可能降至最小，而且提供了对抗血栓的即时保护。”

OrbusNeich为全球60多个国家提供血管疾病的医疗设备。
 
Stent Promotes Tissue Healing
 
A new stent called the Genous bio-engineered R stent is based on a natural healing approach to protect against thrombus and to minimize stenosis. The stent has received the CE Mark.

The developer of the Genous stent, OrbusNeich (Hong Kong) has been selected as the recipient of a 2005 Technology Innovation Award from Frost & Sullivan (Palo Alto, CA, USA). Each year, this award is given to a company that has carried out new research resulting in innovations that have, or will, bring significant contributions to industry.

Genous stents promote tissue healing to occur in a rapid and controlled manner at the stent injury, rather than inhibiting healing, including endothelial coverage, with potent antiproliferative drug-eluting stents. An analysis of interim results of an ongoing clinical study called HEALING II (healthy endothelial accelerated lining inhibits neointimal growth) show that the patients who received the stent and were also on statins had better clinical outcomes. A HEALING III multifactorial clinical study will begin soon to assess the effect of statin therapy with Genous vs bare metal stents.

“Genous is not a drug-eluting stent, there is no polymer or drug,” said David Camp, vice president, sales and marketing. “The stent is coated with an antibody that captures a patient’s own circulating endothelial progenitor cells. This not only minimizes restenosis but also provides immediate protection against thrombus.”

OrbusNeich supplies medical devices for vascular diseases in more than 60 countries around the world.